Meningocele and ankyloblepharon following in utero exposure to olanzapine

Central Institute of Psychiatry, Knake, Jharkhand, India.
European Psychiatry (Impact Factor: 3.44). 08/2006; 21(5):345-6. DOI: 10.1016/j.eurpsy.2006.01.014
Source: PubMed


Although atypical antipsychotics are widely used during pregnancy, their safety is not well established. This case highlights the possible teratogenic effect of olanzapine, in which the baby was born with meningocele and ankyloblepharon. It is suggested that olanzapine may interfere with embryonic development at different stages of pregnancy.

5 Reads
  • Source
    • "Other congenital defects, including meningocele/ankyloblepharon [32], hip dysplasia [33], acheiria [34], and atrioventricular canal defect/unilateral clubfoot [35], have been reported in infants exposed to olanzapine in utero. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Olanzapine use has been reported during pregnancy and breastfeeding, but there are no controlled clinical trials assessing the safety of olanzapine exposure to infants and fetuses. The purpose of this report was to review and analyze prospective post-marketing cases of pregnancy and breastfeeding with olanzapine, in order to guide clinicians and women on the use of olanzapine therapy during pregnancy and/or breastfeeding. A worldwide safety database maintained by Eli Lilly and Company was searched for all spontaneous-reported data regarding olanzapine use during pregnancy and/or breastfeeding. Cases reported prior to pregnancy outcome were considered to be prospective, and follow-up was pursued after the delivery date to assess outcome. Outcome data were available for 610 prospectively identified pregnancies during which olanzapine was used. The majority of women had normal births (66%), although premature births were reported in 9.8% and perinatal conditions in 8% of the pregnancies. A total of 102 pregnancies reported olanzapine treatment during breastfeeding. In these infants, the most commonly reported adverse events were somnolence (3.9%), irritability (2%), tremor (2%), and insomnia (2%), although the majority of pregnancies reported no adverse events (82.3%). The frequency of fetal outcomes in these prospectively identified pregnancies exposed to olanzapine did not differ from rates of outcomes reported in the general population. These data may be useful to help guide clinicians and women decide to continue, or discontinue, olanzapine therapy during pregnancy and/or breastfeeding, but should be considered within the limitations associated with spontaneously reported data. Women should notify their clinicians if they become pregnant or intend to become pregnant while being treated with olanzapine. Because of limited experience in humans, olanzapine should be used in pregnancy only when potential benefit justifies potential risk to the fetus. Olanzapine should only be considered during breastfeeding when the potential benefit justifies the potential risk to the infant.
    BMC pharmacology & toxicology 08/2013; 14(1):38. DOI:10.1186/2050-6511-14-38
  • Source
    • "The annual incidence of psychosis in pregnant women has been reported to be 7.1 cases per 100,000 women; reducing the dose of or discontinuing medication in pregnant women with psychosis may increase the risk of relapse (Arora and Praharaj, 2006). An increasing number of individuals with chronic mental diseases are now integrated into society. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stabilized patients who receive clozapine may wish to have children; but studies on pregnant women receiving clozapine treatment are limited. In this study, we report on clozapine use during pregnancy in two women. The first woman (Case 1) had two deliveries while she was receiving clozapine treatment for schizophrenia. Both her deliveries were term, uncomplicated vaginal deliveries, and the clozapine dose was reduced throughout pregnancy. The second woman (Case 2) developed schizophrenia after her first child was born. She became pregnant after clozapine initiation. She delivered twins by term, uncomplicated vaginal delivery. In our cases, no specific risks for the mothers and their children can be attributed to the use of clozapine. Physicians must be aware of the changes in fertility induced by prolactin-sparing drugs. Mothers who receive clozapine treatment should not be advised to breastfeed their children.
    Journal of Psychopharmacology 02/2008; 22(1):111-3. DOI:10.1177/0269881107079171 · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This is a case report of a 33 year old woman with a history of psychosis, who presented to the women's mental health clinic for consultation at the 12(th) week of gestation, having already received olanzapine throughout the first trimester. She was followed from that point on at our clinic and remained on small doses of olanzapine for the rest of her pregnancy, which was uncomplicated. She gave birth to a healthy female, which at the age of three months was diagnosed with developmental dysplasia of the hip and subsequently received appropriate treatment with favorable outcome. The possibility of the association of this congenital dysplasia with the use of olanzapine during pregnancy is further discussed in this paper.
    Archives of Women s Mental Health 08/2006; 9(4):219-22. DOI:10.1007/s00737-006-0138-8 · 2.16 Impact Factor
Show more